课题基金 / 基金详情

CHEMOTHERAPY INTENSIFICATION THROUGH INTERVAL COMPRESSION IN EWING'S SARCOMA

CHEMOTHERAPY INTENSIFICATION THROUGH INTERVAL COMPRESSION IN EWING'S SARCOMA
通过间隔压缩对尤文氏肉瘤进行强化化疗
批准号:
7375507
负责人:
YOUSIF H MATLOUB
金额:
$2.65万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-12-01 至 2006-11-30

项目摘要

项目成果

YOUSIF H MATLOUB的其他基金

相似基金

相关文献

中文摘要
翻译
该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者(PI)可能从另一个NIH来源获得了主要资金,因此可以在其他CRISP条目中表示。所列机构为中心,不一定是研究者所在机构。本研究不再招募患者。 (来自国家癌症研究所PDQ数据库的临床试验总结)化疗中使用的药物以不同的方式阻止肿瘤细胞分裂,使其停止生长或死亡。放射治疗使用高能x射线来破坏肿瘤细胞。目前尚不清楚哪种化疗方案联合放射治疗和/或手术治疗尤文肉瘤或原始神经外胚层肿瘤更有效。 这是一项随机III期试验,旨在比较不同化疗方案联合放疗和/或手术治疗尤文肉瘤或原始神经外胚层肿瘤患者的有效性。 患者将被随机分配至两组之一。第1组患者将接受联合化疗,每3周输注2-5天,最多4个疗程。第2组患者将接受联合化疗,每2周输注2-5天,最多6个疗程。 从第13周开始,两组中的一些患者将接受手术切除肿瘤,然后进行化疗,伴或不伴放射治疗。其他患者将在手术前接受放射治疗,然后接受额外的放射治疗加化疗,或接受单独的放射治疗加化疗。患者将每3个月接受一次评价,持续4年,每6个月接受一次评价,持续1年。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is no longer recruiting patients. (Clinical trial summary from the National Cancer Institute's PDQ database) Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which chemotherapy regimen combined with radiation therapy and/or surgery is more effective in treating Ewing's sarcoma or primitive neuroectodermal tumor. This is a randomized Phase III trial to compare the effectiveness of different chemotherapy regimens combined with radiation therapy and/or surgery in treating patients who have Ewing's sarcoma or primitive neuroectodermal tumor. Patients will be randomly assigned to one of two groups. Patients in Group 1 will receive infusions of combination chemotherapy on 2-5 days every 3 weeks for up to four courses. Patients in Group 2 will receive infusions of combination chemotherapy on 2-5 days every 2 weeks for up to six courses. Beginning in Week 13, some patients in both groups will undergo surgery to remove the tumor followed by chemotherapy with or without radiation therapy. Other patients will either undergo radiation therapy before surgery followed by additional radiation therapy plus chemotherapy or undergo radiation therapy alone plus chemotherapy. Patients will be evaluated every 3 months for 4 years and every 6 months for 1 year.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
COMPARISON OF DIFFERENT COMBINATION CHEMOTHERAPY REGIMENS IN CHILDREN WITH ALL
  • 批准号:
    7607499
  • 项目类别:
  • 资助金额:
    $0.24万
  • 财政年份:
    2006
  • 负责人:
    YOUSIF H MATLOUB
  • 依托单位:
HIGH RISK B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
  • 批准号:
    7607545
  • 项目类别:
  • 资助金额:
    $0.46万
  • 财政年份:
    2006
  • 负责人:
    YOUSIF H MATLOUB
  • 依托单位:
COMPARISON OF CHEMOTHERAPY REGIMENS IN CHILDREN WITH RHABDOMYOSARCOMA
  • 批准号:
    7607544
  • 项目类别:
  • 资助金额:
    $0.24万
  • 财政年份:
    2006
  • 负责人:
    YOUSIF H MATLOUB
  • 依托单位:
STANDARD RISK B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
  • 批准号:
    7607542
  • 项目类别:
  • 资助金额:
    $1.52万
  • 财政年份:
    2006
  • 负责人:
    YOUSIF H MATLOUB
  • 依托单位:
海外基金